0000899243-22-035443.txt : 20221109
0000899243-22-035443.hdr.sgml : 20221109
20221109164050
ACCESSION NUMBER: 0000899243-22-035443
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20221107
FILED AS OF DATE: 20221109
DATE AS OF CHANGE: 20221109
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: ALTSHULER DAVID
CENTRAL INDEX KEY: 0001550395
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-19319
FILM NUMBER: 221373319
MAIL ADDRESS:
STREET 1: C/O VERTEX PHARMACEUTICALS INCORPORATED
STREET 2: 130 WAVERLY STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: VERTEX PHARMACEUTICALS INC / MA
CENTRAL INDEX KEY: 0000875320
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 043039129
STATE OF INCORPORATION: MA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 6173416393
MAIL ADDRESS:
STREET 1: 50 NORTHERN AVENUE
CITY: BOSTON
STATE: MA
ZIP: 02210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-11-07
0
0000875320
VERTEX PHARMACEUTICALS INC / MA
VRTX
0001550395
ALTSHULER DAVID
C/O VERTEX PHARMACEUTICALS INCORPORATED
50 NORTHERN AVENUE
BOSTON
MA
02210
0
1
0
0
EVP, Global Research and CSO
Common Stock
2022-11-07
4
M
0
1303
187.53
A
37380
D
Common Stock
2022-11-07
4
S
0
140
299.72
D
37240
D
Common Stock
2022-11-07
4
S
0
210
300.96
D
37030
D
Common Stock
2022-11-07
4
S
0
189
301.99
D
36841
D
Common Stock
2022-11-07
4
S
0
261
303.21
D
36580
D
Common Stock
2022-11-07
4
S
0
280
304.58
D
36300
D
Common Stock
2022-11-07
4
S
0
140
305.39
D
36160
D
Common Stock
2022-11-07
4
S
0
83
306.57
D
36077
D
Stock Option (Right to Buy)
187.53
2022-11-07
4
M
0
1303
0.00
D
2029-02-05
Common Stock
1303
1304
D
Transaction made pursuant to Mr. Altshuler's company approved trading plan under Rule 10b5-1.
Mr. Altshuler undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
Open market sales reported on this line occurred at a weighted average price of $299.72 (range $299.46 to $299.97).
Open market sales reported on this line occurred at a weighted average price of $300.96 (range $300.54 to $301.18).
Open market sales reported on this line occurred at a weighted average price of $301.99 (range $301.84 to $302.20).
Open market sales reported on this line occurred at a weighted average price of $303.21 (range $302.89 to $303.45).
Open market sales reported on this line occurred at a weighted average price of $304.58 (range $304.14 to $304.91).
Open market sales reported on this line occurred at a weighted average price of $305.39 (range $305.38 to $305.39).
Open market sales reported on this line occurred at a weighted average price of $306.57 (range $306.45 to $307.22).
The option vests in 16 quarterly installments from 2/6/2019.
/s/ Christiana Stevenson, Attorney-in-Fact
2022-11-09